With glucocorticoid replacement
GH-axis stimulation can reduce cortisone-to-cortisol conversion and unmask or worsen adrenal insufficiency.
Interaction evidence sourceGrowth hormone
Prepared by the ezGLP team. Sources last checked .
Also known as Human Growth Hormone
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Somatropin (HGH) is listed in the ezGLP knowledgebase under Growth hormone. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
No validated PubMed or DOI link is currently curated for this entry.
Common or reported: edema, joint or muscle pain, tingling or carpal-tunnel symptoms, headache, injection-site reactions.
Serious or important: intracranial hypertension, glucose intolerance or diabetes, adrenal insufficiency, pancreatitis, malignancy-related warnings.
Safety evidence sourceThese are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
GH-axis stimulation can reduce cortisone-to-cortisol conversion and unmask or worsen adrenal insufficiency.
Interaction evidence sourceGH-axis stimulation can reduce insulin sensitivity and alter glucose control.
Interaction evidence sourceDuplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.
Interaction evidence sourceSummarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.